Cellular and Molecular Life Sciences

, Volume 68, Issue 2, pp 195–203 | Cite as

Endothelin

Review

Abstract

Endothelin-1 is the most potent vasoconstrictor agent currently identified, and it was originally isolated and characterized from the culture media of aortic endothelial cells. Two other isoforms, termed endothelin-2 and endothelin-3, were subsequently identified, along with structural homologues isolated from the venom of Actractapis engaddensis known as the sarafotoxins. In this review, we will discuss the basic science of endothelins, endothelin-converting enzymes, and endothelin receptors. Only concise background information pertinent to clinical physician is provided. Next we will describe the pathophysiological roles of endothelin-1 in pulmonary arterial hypertension, heart failure, systemic hypertension, and female malignancies, with emphasis on ovarian cancer. The potential intervention with pharmacological therapeutics will be succinctly summarized to highlight the exciting pre-clinical and clinical studies within the endothelin field. Of note is the rapid development of selective endothelin receptor antagonists, which has led to an explosion of research in the field.

Keywords

Endothelin Endothelin-converting enzymes Endothelin receptor Endothelin signal Pathophysiology 

Notes

Acknowledgments

Due to restricted space, we apologize to those whose work is not described in this review. Work from our laboratory that is cited in this review has been supported by grants from the Merck Company Foundation, Banyu Fellowship in Cardiovascular Medicine, the National Institutes of Health (NIH: DK080640), and the Japan Society for the Promotion of Science (JSPS: S-10707). We thank Charisse Montgomery for her editorial support. Y. Kawanabe is the recipient of the Merck Company Foundation and Banyu fellowship awards in cardiovascular medicine.

References

  1. 1.
    Gray GA, Webb DJ (1996) The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 72(2):109–148PubMedCrossRefGoogle Scholar
  2. 2.
    Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411–415PubMedCrossRefGoogle Scholar
  3. 3.
    Kedzierski RM, Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851–876PubMedCrossRefGoogle Scholar
  4. 4.
    Emoto N, Yanagisawa M (1995) Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270(25):15262–15268PubMedCrossRefGoogle Scholar
  5. 5.
    Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M (2000) Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105(10):1373–1382PubMedCrossRefGoogle Scholar
  6. 6.
    Turner AJ, Murphy LJ (1996) Molecular pharmacology of endothelin-converting enzymes. Biochem Pharmacol 51(2):91–102PubMedCrossRefGoogle Scholar
  7. 7.
    Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H (1997) Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 159(4):1987–1992PubMedGoogle Scholar
  8. 8.
    Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D’Orleans-Juste P (2009) Chymase-dependent conversion of big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 328(2):540–548PubMedCrossRefGoogle Scholar
  9. 9.
    Ortmann J, Nett PC, Celeiro J, Traupe T, Tornillo L, Hofmann-Lehmann R, Haas E, Frank B, Terraciano LM, Barton M (2005) Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 334(2):689–695PubMedCrossRefGoogle Scholar
  10. 10.
    Ohnaka K, Takayanagi R, Yamauchi T, Okazaki H, Ohashi M, Umeda F, Nawata H (1990) Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commun 168(3):1128–1136PubMedCrossRefGoogle Scholar
  11. 11.
    Matsumoto T, Ozawa Y, Taguchi K, Kobayashi T, Kamata K (2010) Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. Peptides 31(2):346–353PubMedCrossRefGoogle Scholar
  12. 12.
    Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78(3):473–485PubMedCrossRefGoogle Scholar
  13. 13.
    Takayanagi R, Liu W, Ito T, Ohnaka K, Nawata H (1998) Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1. J Cardiovasc Pharmacol 31(Suppl 1):S62–S63PubMedCrossRefGoogle Scholar
  14. 14.
    Valdenaire O, Rohrbacher E, Mattei MG (1995) Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 270(50):29794–29798PubMedCrossRefGoogle Scholar
  15. 15.
    Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, Raz I (2004) Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41(2):131–140PubMedCrossRefGoogle Scholar
  16. 16.
    Lambert LA, Whyteside AR, Turner AJ, Usmani BA (2008) Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer 99(7):1114–1120PubMedCrossRefGoogle Scholar
  17. 17.
    Dupuis J, Goresky CA, Fournier A (1996) Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81(4):1510–1515PubMedGoogle Scholar
  18. 18.
    Dupuis J, Stewart DJ, Cernacek P, Gosselin G (1996) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94(7):1578–1584PubMedGoogle Scholar
  19. 19.
    Goddard J, Webb DJ (1999) Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. Drugs R D 2(1):1–12PubMedCrossRefGoogle Scholar
  20. 20.
    Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348(6303):730–732PubMedCrossRefGoogle Scholar
  21. 21.
    Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348(6303):732–735PubMedCrossRefGoogle Scholar
  22. 22.
    Hosoda K, Nakao K, Hiroshi A, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S, Imura H (1991) Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287(1–2):23–26PubMedCrossRefGoogle Scholar
  23. 23.
    Davenport AP, O’Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A (1993) Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22(Suppl 8):S22–S25PubMedCrossRefGoogle Scholar
  24. 24.
    Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H (1991) Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett 282(1):103–106PubMedCrossRefGoogle Scholar
  25. 25.
    Luscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102(19):2434–2440PubMedGoogle Scholar
  26. 26.
    Luscher TF (1990) Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. Lung 168(Suppl):27–34PubMedCrossRefGoogle Scholar
  27. 27.
    Griendling KK, Tsuda T, Alexander RW (1989) Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J Biol Chem 264(14):8237–8240PubMedGoogle Scholar
  28. 28.
    Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, Goto K, Masaki T, Yamashita K (1990) Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J Clin Invest 85(3):653–658PubMedCrossRefGoogle Scholar
  29. 29.
    Eguchi S, Hirata Y, Imai T, Marumo F (1993) Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature. Endocrinology 132(2):524–529PubMedCrossRefGoogle Scholar
  30. 30.
    Eguchi S, Hirata Y, Marumo F 1993 Endothelin subtype B receptors are coupled to adenylate cyclase via inhibitory G protein in cultured bovine endothelial cells. J Cardiovasc Pharmacol 22 (Suppl) 8: S161–3Google Scholar
  31. 31.
    Kawanabe Y, Okamoto Y, Hashimoto N, Masaki T (2004) Molecular mechanisms for activation of voltage-independent Ca2 + channels by endothelin-1/endothelin-A receptors. J Cardiovasc Pharmacol 44(Suppl 1):S219–S223PubMedCrossRefGoogle Scholar
  32. 32.
    Gohla A, Offermanns S, Wilkie TM, Schultz G (1999) Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem 274(25):17901–17907PubMedCrossRefGoogle Scholar
  33. 33.
    Aramori I, Nakanishi S (1992) Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem 267(18):12468–12474PubMedGoogle Scholar
  34. 34.
    Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T, Nakanishi S (1993) Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 43(2):127–131PubMedGoogle Scholar
  35. 35.
    Kawanabe Y, Okamoto Y, Miwa S, Hashimoto N, Masaki T (2002) Molecular mechanisms for the activation of voltage-independent Ca2 + channels by endothelin-1 in Chinese hamster ovary cells stably expressing human endothelin(A) receptors. Mol Pharmacol 62(1):75–80PubMedCrossRefGoogle Scholar
  36. 36.
    Masaki T, Miwa S, Sawamura T, Ninomiya H, Okamoto Y (1999) Subcellular mechanisms of endothelin action in vascular system. Eur J Pharmacol 375(1–3):133–138PubMedCrossRefGoogle Scholar
  37. 37.
    Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaki T, Goto K (1995) Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors. Eur J Biochem 228(1):102–108PubMedCrossRefGoogle Scholar
  38. 38.
    Kawanabe Y, Okamoto Y, Nozaki K, Hashimoto N, Miwa S, Masaki T (2002) Molecular mechanism for endothelin-1-induced stress-fiber formation: analysis of G proteins using a mutant endothelin(A) receptor. Mol Pharmacol 61(2):277–284PubMedCrossRefGoogle Scholar
  39. 39.
    Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328(24):1732–1739PubMedCrossRefGoogle Scholar
  40. 40.
    Corder R, Carrier M, Khan N, Klemm P, Vane JR (1995) Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 26(Suppl 3):S56–S58PubMedGoogle Scholar
  41. 41.
    Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S (1995) Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26(7):1581–1585PubMedCrossRefGoogle Scholar
  42. 42.
    Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114(6):464–469PubMedGoogle Scholar
  43. 43.
    Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ (2002) Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105(9):1034–1036PubMedCrossRefGoogle Scholar
  44. 44.
    Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y (2001) Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 18(1):5–14PubMedCrossRefGoogle Scholar
  45. 45.
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119–1123PubMedCrossRefGoogle Scholar
  46. 46.
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903PubMedCrossRefGoogle Scholar
  47. 47.
    Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR (2004) Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169(4):441–447PubMedCrossRefGoogle Scholar
  48. 48.
    Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85(2):504–509PubMedGoogle Scholar
  49. 49.
    Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27(3):633–641PubMedCrossRefGoogle Scholar
  50. 50.
    Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pacher R (1998) Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32(6):1695–1700PubMedCrossRefGoogle Scholar
  51. 51.
    Ponicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Bohm M, Zerkowski HR, Brodde OE (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97(8):744–751PubMedGoogle Scholar
  52. 52.
    Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Bohm M (1999) Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99(16):2118–2123PubMedGoogle Scholar
  53. 53.
    Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ (1998) Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 352(9123):201–202PubMedCrossRefGoogle Scholar
  54. 54.
    Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346(8977):732–736PubMedCrossRefGoogle Scholar
  55. 55.
    Spieker LE, Mitrovic V, Noll G, Pacher R, Schulze MR, Muntwyler J, Schalcher C, Kiowski W, Luscher TF (2000) Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 35(7):1745–1752PubMedCrossRefGoogle Scholar
  56. 56.
    Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42(1):140–147PubMedCrossRefGoogle Scholar
  57. 57.
    Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A (2001) Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 3(4):457–461PubMedCrossRefGoogle Scholar
  58. 58.
    Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G (2003) RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41(2):204–210PubMedCrossRefGoogle Scholar
  59. 59.
    O’Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41(9):1452–1457PubMedCrossRefGoogle Scholar
  60. 60.
    O’Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M (2002) Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). Am Heart J 144(4):583–588PubMedGoogle Scholar
  61. 61.
    Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W (2001) The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142(2):340–349PubMedCrossRefGoogle Scholar
  62. 62.
    Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C (2001) A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 120(2):460–466PubMedCrossRefGoogle Scholar
  63. 63.
    Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I, Pratt CM (2001) Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 103(7):973–980PubMedGoogle Scholar
  64. 64.
    Kalra PR, Moon JC, Coats AJ (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85(2–3):195–197PubMedCrossRefGoogle Scholar
  65. 65.
    Mylona P, Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure Cardio.net Editorial Team. Eur J Heart Fail 1(2):197–200PubMedCrossRefGoogle Scholar
  66. 66.
    Iwasa S, Fan J, Miyauchi T, Watanabe T (2001) Blockade of endothelin receptors reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Pathobiology 69(1):1–10PubMedCrossRefGoogle Scholar
  67. 67.
    Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, Hamada T, Otani S, Yanagisawa M, Takeda T (1991) Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 114(3):213–215PubMedGoogle Scholar
  68. 68.
    Barton M, Shaw S, d’Uscio LV, Moreau P, Luscher TF (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238(3):861–865PubMedCrossRefGoogle Scholar
  69. 69.
    Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14(6 Pt 2):83S–89SGoogle Scholar
  70. 70.
    Barton M (2008) Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 4(9):490–501PubMedCrossRefGoogle Scholar
  71. 71.
    Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK (1999) Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 96(12):6920–6924PubMedCrossRefGoogle Scholar
  72. 72.
    Barton M (2000) Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2(1):84–91PubMedCrossRefGoogle Scholar
  73. 73.
    Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A (1999) Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 100(16):1680–1683PubMedGoogle Scholar
  74. 74.
    Agapitov AV, Haynes WG (2002) Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Sys 3(1):1–15CrossRefGoogle Scholar
  75. 75.
    Moreau P, d’Uscio LV, Shaw S, Takase H, Barton M, Luscher TF (1997) Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 96(5):1593–1597PubMedGoogle Scholar
  76. 76.
    Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, Kumada M (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 276(4 Pt 2):R1071–7Google Scholar
  77. 77.
    Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33(1 Pt 2):581–585Google Scholar
  78. 78.
    Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93(10):1860–1870PubMedGoogle Scholar
  79. 79.
    Haynes WG, Webb DJ (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344(8926):852–854PubMedCrossRefGoogle Scholar
  80. 80.
    Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension Investigators. N Engl J Med 338(12):784–790PubMedCrossRefGoogle Scholar
  81. 81.
    Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ (2004) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109(9):1186–1193PubMedCrossRefGoogle Scholar
  82. 82.
    Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ (2004) Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15(10):2601–2610PubMedCrossRefGoogle Scholar
  83. 83.
    Dhaun N, Goddard J, Webb DJ (2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17(4):943–955PubMedCrossRefGoogle Scholar
  84. 84.
    Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ (2009) Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54(1):113–119PubMedCrossRefGoogle Scholar
  85. 85.
    Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M (2009) Endothelin receptor antagonism and cancer. Eur J Clin Invest 39(Suppl 2):74–77PubMedCrossRefGoogle Scholar
  86. 86.
    Bagnato A, Catt KJ (1998) Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 9(9):378–383PubMedCrossRefGoogle Scholar
  87. 87.
    Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG (1999) Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59(3):720–727PubMedGoogle Scholar
  88. 88.
    Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ (1995) Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1(9):1059–1066PubMedGoogle Scholar
  89. 89.
    Rosano L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65(24):11649–11657PubMedCrossRefGoogle Scholar
  90. 90.
    Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG, Bagnato A (2000) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157(5):1537–1547PubMedGoogle Scholar
  91. 91.
    Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11(17):6300–6310PubMedCrossRefGoogle Scholar
  92. 92.
    Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y (1988) Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 238(2):249–252PubMedCrossRefGoogle Scholar
  93. 93.
    Vacca F, Bagnato A, Catt KJ, Tecce R (2000) Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60(18):5310–5317PubMedGoogle Scholar
  94. 94.
    Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER (2009) Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 20(14):3374–3389PubMedCrossRefGoogle Scholar
  95. 95.
    Spinella F, Rosano L, Elia G, Di Castro V, Natali PG, Bagnato A (2004) Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol 44(Suppl 1):S140–S143PubMedCrossRefGoogle Scholar
  96. 96.
    Spinella F, Rosano L, Decandia S, Di Castro V, Albini A, Elia G, Natali PG, Bagnato A (2006) Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood) 231(6):1123–1127Google Scholar
  97. 97.
    Jimeno A, Carducci M (2005) Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 5(3):419–427PubMedCrossRefGoogle Scholar
  98. 98.
    Rosano L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A (2006) ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 231(6):1132–1135Google Scholar
  99. 99.
    Warren R, Liu G (2008) ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 17(8):1237–1245PubMedCrossRefGoogle Scholar
  100. 100.
    Growcott JW (2009) Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 20(2):83–88PubMedCrossRefGoogle Scholar
  101. 101.
    Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106(8):2806–2811PubMedCrossRefGoogle Scholar
  102. 102.
    Rosano L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A (2007) ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6(7):2003–2011PubMedCrossRefGoogle Scholar
  103. 103.
    Rosano L, Spinella F, Di Castro V, Natali PG, Bagnato A (2004) Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol 44(Suppl 1):S132–S135PubMedCrossRefGoogle Scholar
  104. 104.
    Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A (2003) Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63(10):2447–2453PubMedGoogle Scholar
  105. 105.
    Smollich M, Wulfing P (2007) The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5(3):239–248PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  1. 1.Department of NeurosurgeryOtsu Municipal HospitalOtsuJapan
  2. 2.Department of PharmacologyThe University of ToledoToledoUSA

Personalised recommendations